prostatic cancer
Conditions
Interventions
None listed
Sponsors
Zhongnan Hospital of Wuhan University
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Pathologically diagnosed as prostate adenocarcinoma; 2. High-risk metastatic prostate cancer is considered by imaging examinations including PMSA-PET and bone scan: Gleason score >= 8, three or more lesions in bone scan, or measurable internal organs except lymph node metastasis transfer; 3. Have not received any form of anti-tumor therapy including androgen deprivation therapy before; 4. ECOG score <= 2; 5. Immunohistochemical staining of AR-V7 in prostate cancer tissue was positive; 6. Patients who can tolerate androgen deprivation therapy, docetaxel chemotherapy and abiraterone therapy.
Exclusion criteria
Exclusion criteria: 1. Patients with a life expectancy of less than 1 year; 2. Patients with severe mental illness or other reasons that prevent them from cooperating with treatment or follow-up; 3. Patients who fail to standardize treatment according to doctor's orders; 4. Patients with other tumor diseases; 5. Prostate cancer with pathological types other than adenocarcinoma; 6. Patients with severe allergies to gonadotropin-releasing hormone (GnRH) analogues; 7. Blood testosterone cannot reach castration level (<= 50 ng/ml) during treatment; 8. Patients receiving immunosuppressive therapy or with immunodeficiency diseases; 9. Patients with severe liver damage (Child-Pugh class C); 10. Patients with severe renal impairment requiring long-term dialysis treatment; 11. Patients with severe bone marrow suppression and severe neutropenia; 12. Participate in other clinical studies from 30 days before enrollment to the completion of this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival;Progression Free Survival; | — |
Countries
China
Contacts
Public ContactHua Xu
Zhongnan Hospital of Wuhan University
Outcome results
None listed